1	Engineered phage endolysin eliminates Gardnerella in bacterial vaginosis without
2	damaging the healthy vaginal microbiome
3	
4	Christine LANDLINGER, Dr. <sup>a</sup> , Lenka TISAKOVA, Dr. <sup>a</sup> , Vera OBERBAUER, Ms. <sup>a</sup> , Timo
5	SCHWEBS, Mr. <sup>a</sup> , Agnieszka LATKA, Dr. <sup>b</sup> , Leen VAN SIMAEY, Ms. <sup>b</sup> , Mario
6	VANEECHOUTTE, Prof. <sup>b</sup> , Alexander GUSCHIN, Dr. <sup>c</sup> , Sonja SWIDSINSKI, Dr. <sup>d</sup> ,
7	Alexander SWIDSINSKI, Dr. <sup>e,f</sup> , Lorenzo CORSINI, Dr. <sup>a</sup>
8	
9	<sup>a</sup> PhagoMed Biopharma GmbH, Vienna Biocenter, Austria
10	<sup>b</sup> Laboratory Bacteriology Research, Department of Diagnostic Sciences, Faculty of Medicine
11	& Health Sciences, Ghent University, Flanders, Belgium
12	<sup>c</sup> Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology.Moscow,
13	Russia
14	<sup>d</sup> MDI Limbach Berlin GmbH, Berlin, Germany
15	<sup>e</sup> Medizinische Klinik, Charité CCM, Humboldt Universität, Berlin, Germany
16	<sup>f</sup> Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Moscow,
17	Russia
18	
19	
20	Correspondence to:
21	Lorenzo Corsini
22	PhagoMed Biopharma GmbH
23	Leberstraße 20, 1110 Wien, Austria
24	Tel: +43 6765797380
25	e-mail: Lorenzo.corsini@phagomed.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 2

## 27 Disclosure

- 28 Conflicts of interests have been declared by the following authors: CL, LT, VO, are employees
- of PhagoMed Biopharma GmbH at the time of the study and LC holds shares in PhagoMed
- 30 Biopharma GmbH and is the inventor on a patent application related to the work described here.
- 31 The research of AS, AL, LVS and MV has been supported financially by PhagoMed Biopharma
- 32 GmbH.
- 33 Funding
- 34 This study was supported by the Austrian Research Promotion Agency (FFG).

#### 35 **Ethics approval**

36 The study was approved by the Charité ethical committee EA1 /088110.

#### 37 Word count of the abstract

38 343 words

## **39 Word count of the main text**

40 5434 words

- Keywords: Gardnerella, prophage, endolysin, bacterial vaginosis, polymicrobial biofilm, 41
- genus-specificity, antimicrobial resistance, alternative to antibiotic treatment 42

4

Background - Bacterial vaginosis is characterized by an imbalance of the vaginal microbiome
in which the normally predominant lactobacilli are replaced by other bacterial species. Initiated
by strains of the bacterium *Gardnerella*, a characteristic biofilm forms on the vaginal
epithelium, explaining the typical presence of clue cells. This biofilm contributes to the
resilience of the bacteria to antibiotic treatment, which may explain the frequent recurrence of
BV.

**Objective -** In this study, we investigate whether a therapy based on bacteriophage endolysins which specifically lyse *Gardnerella*, in particular the drug candidate PM-477, might be a promising alternative to broad-spectrum antibiotics and antiseptics.

Study design - To identify Gardnerella specific endolysins, we searched for endolysin-52 encoding sequences in regions of Gardnerella genomes that are of prophage origin. This search 53 identified fourteen homologous genes predicted to encode 1,4-beta-N-acetylmuramidase-type 54 endolysins. When expressed in Escherichia coli and purified, the recombinant proteins 55 demonstrated strong bactericidal activity against four different Gardnerella species. By 56 shuffling the N-terminal catalytic domains and C-terminal cell wall-binding domains between 57 the homologues, we produced 81 chimeric endolysins. These endolysins were tested for their 58 activity and specificity in vitro and ex-vivo on vaginal samples from fifteen BV positive 59 60 patients. Fluorescence in situ hybridization was used for visualization.

**Results -** Several engineered endolysins were 10-fold more active than the most active wildtype enzymes. When tested against a panel of 20 *Gardnerella* strains, the most active endolysin, called PM-477, showed minimum inhibitory concentrations of  $0.13-8 \mu g/ml$ . PM-477 had no effect on *Lactobacillus* strains or other species of vaginal bacteria. Furthermore, the efficacy of PM-477 was tested on vaginal samples from fifteen patients with either first time or recurring bacterial vaginosis. In fourteen cases, PM-477 killed the *Gardnerella* bacteria and physically dissolved the biofilms without affecting the remaining vaginal microbiome.

- 68 Conclusion - The high selectivity and effectiveness in eliminating Gardnerella, both in cultures
- of isolated strains as well as in clinically derived samples of natural polymicrobial biofilms, 69
- makes PM-477 a promising drug candidate and an alternative to antibiotics for the treatment of 70
- 71 bacterial vaginosis, especially in patients with frequent recurrence.

6

#### 72 Background

Bacterial vaginosis (BV) is a very common disorder in women of reproductive age, with a 73 prevalence estimated at 10–30 % worldwide <sup>1,2</sup>. It is caused by an imbalance in the normal, 74 healthy microbiome of the vagina that results mostly in discharge, odor and irritation. BV is 75 associated with an increased risk of preterm delivery and low birthweight <sup>3,4</sup>, infertility and 76 early spontaneous abortion 5-7, and it is also a high risk factor for contracting sexually 77 transmitted diseases, including HIV<sup>8,9</sup>. Besides these potentially severe physiological 78 consequences, frequently recurring and strongly symptomatic BV can have a huge negative 79 impact on some women's quality of life and psychological wellbeing. 80

81 The healthy vaginal microbiome is characterized by a low diversity and uniform colonization by a few species of Lactobacillus <sup>10</sup>. In BV, the imbalance in the vaginal microbiome is 82 represented predominantly by the loss of beneficial lactobacilli and overgrowth of bacteria such 83 as Gardnerella, Prevotella, Atopobium, and Sneathia<sup>11</sup> and Lactobacillus iners<sup>12</sup>. The current 84 model of the etiology of BV focuses on the importance of *Gardnerella* species. It postulates 85 86 that virulent strains of Gardnerella form an adherent biofilm on the vaginal epithelium in which other species can proliferate, resulting in a polymicrobial biofilm <sup>13–17</sup>. This adherent biofilm is 87 only weakly affected by the innate immune response <sup>18</sup>, and the interplay with the host immune 88 system is only partially understood <sup>19</sup>. BV development may be triggered by sexual transmission 89 of a mix of bacteria including *Gardnerella*, which can adhere to epithelial cells in the presence 90 of lactobacilli. It has been suggested that, unlike strictly anaerobic bacteria associated with BV, 91 Gardnerella, a facultative anaerobe, can tolerate the high redox potential created by the 92 Lactobacillus-dominated healthy vaginal microbiome<sup>15,20,21</sup>. The metabolism of Gardnerella 93 *spp.*, in turn, results in a local increase in pH and decrease of the redox potential, favoring 94 growth of iron-dependent anaerobes <sup>10</sup> and suppression of lactobacilli <sup>22</sup>. Recently, the species 95 previously known as Gardnerella vaginalis was shown to comprise at least 13 different species 96 of which four were named <sup>23</sup>. Clinical studies indicated that various *Gardnerella* species may 97

7

contribute differently to the pathogenesis of BV. A higher abundance of *G. vaginalis* and *G. swidsinskii* was found to be related with vaginal symptoms of abnormal odor and discharge and
the relative abundances of *G. vaginalis*, *G. swidsinskii*, and *G. piotii* but not *G. leopoldii* were
strongly associated with BV microbiome <sup>24,25</sup>.

The therapies used currently to treat BV are broad-spectrum antibiotics, mainly metronidazole 102 (MDZ), tinidazole (TDZ), or clindamycin (CLI), antiseptics (such as Octenisept<sup>®</sup>, based on the 103 detergent-like octenidin), probiotics (preparations of lactobacilli), and prebiotics (lactate gels). 104 Although all of these treatments may have some beneficial effects, none has proven to have 105 satisfactory efficacy in preventing recurrence. Antibiotics are the most effective in quickly 106 107 reducing the symptoms, but they are associated with a recurrence rate of up to 60 % within six months of treatment <sup>26</sup>. One reason may be the presence of an antibiotic-tolerant biofilm in BV 108 that shelters a reservoir of persister cells <sup>26,27</sup>. Antibiotic treatment not only often fails to 109 eradicate the biofilm, but can also lead to further dysbiosis of the vaginal microbiome and can 110 promote candidiasis <sup>28</sup>. Moreover, CLI can trigger pseudomebrannous colitis, cause antibiotics 111 associated diarrhea and other gastro-intestinal side effects <sup>29,30</sup>. Also, *Gardnerella* strains 112 frequently develop resistance to MDZ and TDZ<sup>31</sup>. Antiseptic treatments for BV have been less 113 well studied than antibiotics but they are similar with regard to their effectiveness and are also 114 associated with high recurrence rates and deterioration of the healthy vaginal microbiome  $^{16,32}$ . 115 Studies of probiotics, and prebiotics are generally inconclusive: they appear not to result in 116 lasting benefits <sup>26</sup>. Vaginal microbiome transplantation after a course of antibiotic treatment 117 118 had a promising effect in one study of five patients, but the approach is very resource-intense and hardly scalable <sup>33</sup>. In conclusion, novel treatments that offer an alternative to antibiotics or 119 that can be used in combination with antibiotics, are urgently needed. 120

Bacteriophage-encoded peptidoglycan hydrolases – also called endolysins or 'enzybiotics' – are a promising alternative to antibiotics <sup>34,35</sup>. Produced towards the end of the lytic cycle in phage-infected bacteria, these enzymes cleave peptidoglycan in the bacterial cell wall, thus

8

lysing the cells and releasing the progeny phages. They have been shown to be particularly 124 effective against Gram-positive bacteria, which lack the Gram-negative outer membrane that 125 might limit accessibility to the cell wall peptidoglycan. Endolysins have several advantages 126 over antibiotics; not least, their very narrow host spectrum, which is usually limited to a single 127 genus or even a single species <sup>36</sup>, and their low propensity to generate resistance in their hosts 128 <sup>37</sup>. Bacteriophages that invade Gram-positive bacteria encode a variety of highly diverse 129 endolysins. In general, they have a modular structure consisting of one or more enzymatically 130 active domain (EAD)s connected by a flexible interdomain linker to at least one cell wall-131 binding domain (CBD), typically located at the C-terminus of the protein. Both domains can 132 contribute to the specificity for a given genus or species of bacteria<sup>38</sup>. 133

134 Although no bacteriophages that infect *Gardnerella* species have yet been isolated, prophages encoding for endolysins are present in the Gardnerella genomes. Phage endolysins are a 135 potentially novel and promising approach to treat BV because Gardnerella, now generally 136 acknowledged as the central agent in the etiology of BV, has a thin cell wall. To develop 137 endolysins specific for Gardnerella, we used an in silico approach to identify the genes 138 encoding endolysins. We cloned and sequenced 14 such genes, demonstrated the lytic activity 139 and specificity of purified recombinant proteins for *Gardnerella* spp. and engineered an enzyme 140 with enhanced activity by domain shuffling. Moreover, we demonstrate the efficacy and 141 specificity of this engineered endolysin on biofilms of Gardnerella in samples from patients 142 with BV. 143

144

#### 145 Material and Methods

#### 146 Bacterial strains and culture conditions

Atopobium vaginae, Gardnerella spp., Lactobacillus iners, Mobiluncus spp, Streptococcus
agalactiae, Prevotella bivia, and and were obtained from the Laboratory of Bacteriology,
University of Ghent, Belgium. Other Lactobacillus spp. were obtained from the German

9

Collection of Microorganisms (DSMZ). Gardnerella strains were either grown on chocolate 150 (Choc) agar plates (Becton Dickinson) under anaerobic conditions in an anaerobic chamber 151 equipped with anaerobic atmosphere generation bags (Sigma Aldrich) for 24-48 h. 152 Lactobacillus spp. were cultured on Schaedler plates supplemented with vitamin K1 and 5 % 153 sheep blood (Becton Dickinson), anaerobically at 37 °C for 24-48 h. A. vaginae, M. curtisii, 154 M. mulieris, S. agalactiae, and P. bivia were either grown on Columbia blood agar plates, 155 supplemented with 5 % sheep blood (Becton Dickinson) or Schaedler agar plates supplemented 156 with vitamin K1 and 5 % sheep blood, anaerobically at 37 °C for 48 h. Escherichia coli 157 BL21(DE3) cells (New England Biolabs) were used for protein expression and were grown on 158 159 Luria Bertani (LB) agar plates (Becton Dickinson) or in LB (Luria/Miller) broth (Carl Roth) 160 supplemented with appropriate selection antibiotic, aerobically at 37 °C. Liquid cultures of all species were done in New York City (NYC) broth III (10 mM HEPES (Sigma Aldrich), 15 g/L 161 162 Proteose Peptone (Sigma Aldrich), 3.8 g/L yeast extract (Thermo Fisher Scientific), 86 mM sodium chloride (Carl Roth), 28 mM α-D-glucose (Sigma Aldrich)), supplemented with 10 % 163 horse serum (HS) (Thermo Fisher Scientific). 164

#### 165 Identification of Gardnerella genes encoding endolysin within prophage regions

Prophage regions in *Gardnerella* genomic sequences were identified by using PHASTER (https://phaster.ca/) to scan translated nucleotide sequences of *Gardnerella* genome entries in the NCBI database (https://blast.ncbi.nlm.nih.gov). Protein domain searches for endolysins were performed using INTERPRO (https://www.ebi.ac.uk/interpro/) to identify predicted enzymatically active domains in the corresponding amino acid sequence for each identified phage endolysin.

#### 172 Gene cloning and overexpression of phage endolysins

Briefly, DNA of genes encoding wild-type or genetically engineered endolysins fused to a His<sub>6</sub>tag was synthesized, cloned into the expression vector pET29b(+) and expressed in *E. coli*BL21(DE3). Protein expression was induced by TB (Terrific Broth Medium; 24 g/L Bacto

10

Yeast Extract (Becton Dickinson), 12 g/L Bacto Tryptone (Becton Dickinson), 0.4 % glycerol 176 177 (87%; Applichem), 0.02 mM potassium phosphate monobasic (Sigma Aldrich), 0.07 mM dipotassium hydrogen phosphate (Merck) and 1.5 % α-lactose monohydrate (Carl Roth)), by 178 incubating at 25 °C for 24 h, with shaking at 250 rpm/min. The overexpressed proteins were 179 purified by affinity chromatography on a nickel-nitrilotriacetic acid (Ni-NTA) affinity matrix 180 (HISTrap column) eluted with 50 mM MES (Carl Roth) pH 7, 150 mM NaCl (Carl Roth), 250 181 mM imidazole (Carl Roth) and followed by size exclusion chromatography. Fractions were 182 pooled and dialyzed against MES buffer (50 mM MES pH 5.5, 100 mM NaCl, 8 mM MgSO<sub>4</sub> 183 (Sigma Aldrich)). Protein concentration was determined at OD 260/280 nm or by using the 184 Pierce<sup>TM</sup> BCA (bicinchoninic acid) protein assay kit (Thermo Fisher Scientific). 185

#### 186 Culture-based assessment of bactericidal activity

Bacterial suspensions (OD<sub>600</sub> of 0.1, corresponding to approximately  $10^7-10^8$  CFU/ml) were 187 188 prepared by scraping the cells from confluently grown agar plates and diluting them into NYCIII+ 10 % HS, pH 5.5. Reactions were performed in triplicate by mixing 10 µl of endolysin 189 (200 µg/ml) with 90 µl bacterial suspension in the wells of a 96-well plate. Ten µl MES buffer 190 without the endolysin was used as a control. The 96-well reaction plate was incubated 191 anaerobically at 37 °C for 5 h. Tenfold dilution series (10<sup>-1</sup> to 10<sup>-6</sup>) of the cell reaction mixtures 192 were prepared in NYCB+ 10 % HS and 2 µl of each dilution were spotted onto Choc agar plates. 193 After anaerobic incubation at 37 °C for 48 h, colonies were counted, CFU/ml calculated, and 194 the log<sub>10</sub> reduction compared to MES buffer treated control was determined. 195

#### 196 *MIC assessment*

197 The minimum inhibitory concentration (MIC), which is a standard measure of the activity of 198 antimicrobials, was determined according to the Clinical and Laboratory Standards Institute 199 protocol (2018) *Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria* <sup>39</sup>. 200 Bacterial suspensions of 10<sup>5</sup> to 10<sup>6</sup> CFU/ml in NYCIII+ 10 % HS were treated with a 1:2 201 dilution series of either PM-477 (starting concentration 64  $\mu$ g/ml) or the antibiotics

11

metronidazole (Gatt-Koller), tinidazole (Sigma Aldrich), or clindamycin (Clindamycin hydrochloride, Sigma Aldrich), starting with a concentration of 128  $\mu$ g/ml and twofold dilution down to 0.0625  $\mu$ g/ml. Controls for growth in the absence of antimicrobials were also included. OD<sub>620</sub> was recorded by microplate reader (Tecan) after incubation at 37 °C for 48 h or, for some fast-growing strains, after incubation for 24 h, and compared to t=0 values.

207 Phase contrast microscopy

Dense bacterial suspensions were prepared in NYCIII+ 10 % HS either as Gardnerella 208 monocultures or as a co-cultures of *Gardnerella* and *Lactobacillus* strains at final  $OD_{600}$ = 4 for 209 each strain. Bacterial mixtures were centrifuged at 3,800 x g for 7 min at room temperature in 210 a benchtop centrifuge (Heraeus Instruments, Biofuge Pico). Supernatants were removed and 211 212 cell pellets were resuspended in 50 µl of PM-477 (460 µg/ml) or in MES buffer alone as a negative control and incubated for 5 h at 37 °C under anaerobic conditions. Subsequently, 5 µl 213 of each bacterial suspension were placed on a glass slide, covered with a glass coverslip and 214 observed by phase contrast microscopy (Olympus BX41 microscope, magnification 1000x). 215

For the comparison of bacteriolytic and bactericidal effects, bacterial suspensions of 216 Gardnerella swidsinskii and Gardnerella vaginalis were prepared in NYCIII+ 10 % HS at a 217 final  $OD_{600}$  = 1. Bacterial suspensions of 50 µl were centrifuged at 3,800 x g for 7 min at room 218 temperature in a benchtop centrifuge (Heraeus Instruments, Biofuge Pico). Supernatants were 219 removed and pellets were resuspended in 50 µl of MES buffer containing PM-477 at 400 µg/ml, 220  $200 \,\mu$ g/ml,  $100 \,\mu$ g/ml,  $50 \,\mu$ g/ml or  $25 \,\mu$ g/ml, or in MES buffer alone as a negative control, and 221 incubated for 5 h at 37 °C in anaerobic conditions. Subsequently, 5 µl of each bacterial 222 suspension were observed by phase contrast microscopy as above. To determine viability, 10 223 µl of the reaction mixture was serially diluted and spotted onto Choc agar plates. After 224 incubation at 37 °C for 48 h, the colonies were counted and CFU/ml was calculated. 225

226 Lytic effects of PM-477 and Octenisept® on ex vivo BV patient samples as detected by

227 fluorescence in situ hybridization (FISH) microscopy

12

Vaginal samples were collected from randomly selected 24-49 year-old Caucasian women who 228 were previously diagnosed with BV according to the Amsel criteria<sup>40</sup>. In addition, the presence 229 of clue cells (epithelial cells covered with cohesive Gardnerella bacteria) was determined by 230 FISH microscopy <sup>16</sup>. Fresh vaginal smears were collected with a swab and put in ESwab<sup>™</sup> 231 493C02 pre-filled vials (COPAN Diagnostics). The vials were vortexed gently, resulting in a 232 suspension that contained epithelial cells and vaginal bacteria. Four consecutive vaginal smears 233 from each patient were pooled. The effects of 0.2, 2, 20 and 200 µg/ml of PM-477 after 2, 6, 234 and 24 h, respectively, were tested either at room temperature or 36 °C. Since the most 235 pronounced lytic effect on Gardnerella was observed after 24 h exposure to 200 µg/ml PM-477 236 237 at 36 °C (Supplementary Table 1), this condition was used for further studies. Subsequently, vaginal swabs from 15 BV patients were collected, aliquoted, and mixed 1:1 (v/v) with 400 238  $\mu$ g/ml PM-477 (final concentration of 200  $\mu$ g/ml) or with MES buffer as a negative control, or 239 mixed 1:20 (v/v) with the disinfectant Octenisept® (Schülke) and incubated for 24 h at 36 °C. 240 Untreated samples were also included in the analyses as baseline controls. The samples were 241 fixed with Carnoy solution (alcohol/chloroform/acetic acid 6/3/1 by volume)<sup>41</sup>. Fields of 10 242 mm x 10 mm were marked on SuperFrost slides (Langenbrinck, Emmendingen, Germany) with 243 a PAP pen (Kisker-Biotech, Steinfurt, Germany). Five µl aliquots of vortexed, fixed vaginal 244 245 smear sample were dropped onto the marked field. The slides were dried for 60 min at 50 °C before FISH analysis. 246

For multicolor FISH analyses, we used the Gard662 *Gardnerella*-specific DNA hybridization probe  $^{42}$  and the universal bacterial probe Eub338  $^{43}$ . Oligonucleotide probes were synthesized with a fluorescent dye (Cy3 or Cy5). The hybridization was performed at 50 °C as previously described  $^{41}$ . The probe Ato291 was used for *Atopobium*, Liner23-2 for *L. iners*, and Lcrisp16-1 for *L. crispatus*  $^{42}$ . DAPI was used to visualize the vaginal epithelial cells (microphotographs not shown). Changes in density and distribution of microbial species were monitored by using a Nikon Eclipse 80i fluorescence microscope, a Nikon SHG1 camera and accompanying

13

software (Nikon, Tokyo, Japan). To avoid dispersion related biases (the thickness of smears on 254 the glass slide and the microbial distribution is uneven), bacteria were enumerated for 255 256 representative areas containing 10 epithelial cells as follows. For bacteria in low densities (e.g. lactobacilli), larger areas, including at least 10 microscopic fields were evaluated and mean cell 257 258 numbers were expressed in relation to 10 epithelial cells. In areas with high local bacterial concentrations (e.g. in patches of biofilms), where cells are adjacent and in part overlapping, 259 260 each 10 µm x 10 µm area covered with bacteria was counted as 500 bacterial cells. The numbers 261 were rounded to full 100s.

#### 262 Statistical analysis

Where appropriate, data were log-normalized prior to applying statistical tests (e.g. for CFU/ml values, and as indicated in the figure legends). When only two groups were compared, the unpaired two-tailed Student's *t*-test was used as indicated in the respective figure legends. Multiple groups were compared by two-tailed one-way ANOVA tests. The software used for statistical analyses was GraphPad Prism8. Differences between groups were considered statistically significant when  $P \le 0.05$ .

269

#### 270 **Results**

#### 271 Gardnerella genomes contain prophage genes that encode active endolysins

Although no bacteriophages of *Gardnerella* species are known, multiple *Gardnerella* genomes 272 that have been sequenced contain DNA regions that are predicted to be of prophage origin <sup>44,45</sup>. 273 To identify endolysins that might target specifically Gardnerella, we used Basic Local 274 Alignment Search Tool (BLAST) to search for sequences with similarities to known endolysin 275 genes in the prophage regions of published Gardnerella genomes. A total of 14 genes were 276 identified that encoded 1,4-beta-N-acetylmuramidases, with sequence similarity between 87 to 277 278 98 %, when compared to each other. Twelve genes encode a 306 residues protein whereas two encode similar proteins that lack 55 residues at the C-terminus (Supplementary Table 2). The 279

14

sequences all encode domain structures common to all known endolysins: an N-terminal EAD of the glycoside hydrolase family 25 (GH25) and a CBD, comprising two CW\_7 motifs, homologous to the CBD of Cpl-7 lysozyme, encoded by the *Streptococcus pneumoniae* bacteriophage Cp-7. The sequences of these putative endolysins are 90–94% identical to some proteins encoded by the genomes of *Atopobium* and *Bifidobacteriaceae* but < 70 % identical to other endolysins, which may already indicate a high specificity for the genus *Gardnerella* (data not shown).

We expressed the 14 predicted endolysin genes (EL1–EL14) as recombinant proteins in E. coli, 287 and ten (EL 1-7 and EL 10-12) yielded sufficient protein to perform further experiments. Their 288 289 lytic activities were tested on representatives of the four Gardnerella species: G. vaginalis (ATCC 14018<sup>T</sup>), G. leopoldii (UGent 09.48), G. piotii (UGent 18.01<sup>T</sup>), and G. swidsinskii 290 (GS10234). Bacterial suspensions of 107-108 CFU/ml were incubated with each of the 10 291 292 endolysins (at 20 µg/ml) or with buffer as a negative control. After a 5 h incubation, we plated the suspensions and quantified the surviving bacteria, measured as colony-forming units 293 (CFU)/ml (Figure 1). Most of the endolysins reduced the CFU/ml of all four Gardnerella 294 species by multiple log<sub>10</sub> units. Only EL5 and EL6 (one of the two truncated proteins mentioned 295 296 above) were completely inactive in this assay. EL3 and EL10 were the most active against all 297 four *Gardnerella* species tested, *G. swidsinskii* GS10234 being the most susceptible with a > 5log<sub>10</sub>-fold reduction in CFU/ml (**Figure 1**). 298

15



#### Effect of natural ELs on Gardnerella spp.

300

Figure 1: Wild-type endolysins are highly active against four different *Gardnerella* species. 301 Suspensions of G. vaginalis (ATCC 14018T), G. leopoldii (UGent 09.48), G. piotii (UGent 302 18.01T), and G. swidsinskii (GS10234) were treated with recombinant endolysins prepared by 303 expression of the naturally occurring genes (EL1–EL7 and EL10–EL12) (see Methods) and the 304 log<sub>10</sub> reduction in viable CFU/ml was determined. The log<sub>10</sub> reduction was calculated by 305 comparing the CFU/ml after endolysin treatment with that of the buffer control (w/o). LOD 306 indicates the limit of detection. 307

308

309

#### Engineering of a Gardnerella endolysin with enhanced bactericidal activity 310

To increase the lytic activity of the endolysins identified above, we used domain shuffling <sup>46,47</sup> 311 to recombine systematically ten of the EADs encoded by the newly identified endolysin genes 312 EL 1-7 and EL 10-12 (annotated as H1-7 and H10-12) with nine CBDs encoded by EL1-5, 313 EL7 and EL10-12 (annotated as B1-5, B7, and B10-12; since EL6 was inactive, we did not 314 use its truncated CBD). All of the 81 resulting chimeric proteins were expressed in E. coli and 315 316 purified by means of their N-terminal His tags. We tested these chimeric endolysins for their bactericidal activity on the abovementioned Gardnerella strains and compared their activity to 317 that of the 10 wild-type endolysins (Figure 2). 318

H12	H11	H10	H	H	£	Ŧ	HB	НŻ	H		
0.0	-0.8	-17	-0.9	-0.3	-13	01	-11	-1.6	-1.9	GV_ATCC 14018	
-0.8	-1.3	-11	-1.4	-0.1	-15	0.7	-13	-1.2	-1.3	Gl_UGent 09.48	
-0.2	-0.8	-1.4	-0.9	-0.4	-11	0.4	-2.9	-1.0	-0.9	Gp_UGent18.01 <sup>T</sup>	81
-1.5	-2.3	-3.2	3.1	-1.8	-3.8	0.0	-4.3	3.5	3.5	Gs_GS10234	
0.2	-0.2	-1.6	-2.0	-0.8	-1.2	0.1	-1.6	-1.2	-0.4	Gv_ATCC 14018 <sup>™</sup>	
-0.9	-0.4	-1.2	-2.2	-0.4	-1.3	0.5	-1.4	-1.1	-0.3	Gl_UGent 09.48	
-0.3	-0.4	-1.2	-1.3	-0.7	-0.9	0.4	-3.1	-2.5	-0.2	Gp_UGent18.01 <sup>†</sup>	B2
-2.1	-0.3	-3.9	-4.2	-2.4	-3.3	0.0	-4.1	-5.4	-1.4	Gs_GS10234	
-0.2	-2.5	-2.7	-3.2	-0.3	-2.8	0.0	-3.0	-2.9	-0.7	Gv_ATCC 14018 <sup>T</sup>	
-12	-2.2	-1.9	-33	-0.5	-3.0	0.4	-2.0	-2.1	-0.7	Gl_UGent 09.48	
-0.6	-1.7	-2.1	-2.0	-0.3	-1.8	0.2	-1.6	-1.6	-0.3	Gp_UGent18.01 <sup>T</sup>	83
-2.5	4.2	-4.9	4.8	-1.6	4.8	-0.3	-5.4	5.4	-1.9	Gs_GS10234	
0.0	-1.7	-2.3	-2.5	-0.4	-1.8	-0.4	-1.9	-2.3	-0.8	GV_ATCC 14018 <sup>T</sup>	
-0.7	-1.7	÷	-3.1	-0.7	-3.0	-0.5	-1.4	-1.8	-0.7	Gl_UGent 09.48	
-0.3	-1.1	-1.7	-17	-0.3	-2.2	-0.4	-1.2	-1.6	-0.7	Gp_UGent18.01 <sup>T</sup>	4
-23	-2.8	-42	-4.0	-1.6	-45	-2.0	-4.0	-45	-2.3	Gs_GS10234	١.,
-0.2	-1.5	-1.2	-1.6	-0.4	0.2	0.1	-1.4	-1.1	-1.8	Gv_ATCC 14018 <sup>T</sup>	
-1.1	-1.7	-0.8	-2.1	-0.5	0.3	0.3	-1.2	4.5	-0.8	Gl_UGent 09.48	_
-0.4	-0.9	-1.2	-1.2	-0.4	-0.1	0.5	-0.6	-2.7	-0.8	Gp_UGent18.01 <sup>T</sup>	55
-2.1	-3.2	-3.5	-3.2	-17	-0.1	0.1	-3.5	-4.7	-3.3	Gs_GS10234	١.,
-0.8	-0.1	-1.4	-1.6	-0.4	-1.6	0.1	-0.9	-1.0	-1.6	Gv_ATCC 14018 <sup>T</sup>	
-0.6	-0.9	-0.8	-2.1	-0.8	-2.2	0.1	-11	-13	-1.2	Gl_UGent 09.48	
-0.4	-0.7	-1.2	-1.2	-0.6	-1.2	-0.4	6.3	-2.6	-0.9	Gp_UGent 18.01 <sup>T</sup>	17
-2.6	-1.9	4.5	3.2	-2.0	4.2	-1.3	-2.8	-6.7	ىل دى	Gs_GS10234	
-1.3	-2.8	-3.5	-3.4	-0.5	-2.5	-3.0	-1.5	-3.6	-2.5	Gv_ATCC 14018 <sup>T</sup>	3
-0.3	-2.2	-1.6	-3.0	-0.7	-3.6	-2.9	-2.2	3.3	-2.3	Gl_UGent 09.48	B
-0.4	-1.4	-2.4	-1.8	-0.6	-11	-1.9	-0.6	-3.8	ίs	$Gp_UGent 18.01^T$	6
-2.9	-4.1	-5.5	-5.1	-1.8	-4.7	-4.8	-3.8	-6.7	-49	Gs_GS10234	
-2.4	0.1	-3.2	-3.5	-1.0	-2.4	-2.9	-1.6	-3.3	-1.5	Gv_ATCC 14018 <sup>T</sup>	
-1.0	-1.6	-1.7	els is	4.5	-1.6	di Li	-2.0	3.0	-1.6	Gl_UGent 09.48	B
-1.0	-1.0	-1.8	-1.9	-0.7	-1.6	-1.8	-0.8	-3.7	-0.8	Gp_UGent18.01 <sup>T</sup>	E
-3.9	-3.5	-4.6	-3.7	-2.7	-4.4	-4.8	-4.2	-6.7	-3.8	Gs_GS10234	
-0.2	-3.0	-3.6	-2.6	-0.4	-2.3	-0.3	-1.3	-2.8	-0.7	Gv_ATCC 14018 <sup>T</sup>	
-1.0	-2.3	-2.8	-3-3	-0.6	-1.9	-1.1	-1.9	-33	-0.6	Gl_UGent 09.48	B
-0.3	-1.3	-1.6	-1.7	-0.3	-1.6	-0.3	-0.5	-3.6	-0.4	Gp_UGent18.01 <sup>T</sup>	12
-1.9	4.1	-5.0	4.1	-1.3	43	6.6	3.7	-6.7	-2.3	Gs_GS10234	

Figure 2: Domain swapping increases the lytic activity of engineered endolysins. Eighty-one constructs comprising all possible combinations of the EAD (H) and CBD (B) domains of 10

17

wild-type endolysins were tested on four different Gardnerella species as in Figure 1. The 323 values represent the log<sub>10</sub> of the ratio of viable cells (CFU/ml; mean of triplicate assays) in 324 endolysin-treated suspensions of Gardnerella compared to buffer control-treated suspensions 325 of the species, as indicated. Blue shades indicate higher bactericidal effect (high reduction in 326 viable CFU/ml) compared to the wild-type endolysin, red shades indicate lower bactericidal 327 effect, and white coloring indicates equal reduction compared to wild-type endolysin (boxed in 328 black). The endolysin candidate with the highest average reduction over four Gardnerella 329 species is boxed in yellow. 330

331

Overall, G. swidsinskii GS10234 was most sensitive to most endolysins - wild-type and 332 333 chimeric. Two of the chimeric endolysins, H2B10 and H2B11, were more active than any wildtype enzyme against all four *Gardnerella* strains, whereas others were more active than any 334 wild-type endolysin against some strains (e.g. H2B12, H5B3, H5B4, H7B3 and H7B11) 335 336 (Figure 2). Overall, chimeric endolysins combining domains H2, H7 or H10 with domains B10, B11 or B12 showed highest bactericidal activity. The combination of H2 and B10 was most 337 effective against any of the four strains and reduced their viability by an average of 4.3 log<sub>10</sub> 338 CFU/ml. We designated this construct PM-477 and chose it for further development as a 339 candidate for the treatment of BV. 340

341

#### 342 Specificity of PM-477 for the genus Gardnerella

We characterized the activity and specificity of PM-477 against panels of 13 *Gardnerella* strains of the four species described above, 12 strains of vaginal lactobacilli (including *L. crispatus*, *L. jensenii* and *L. gasseri*, selected as representative of the healthy vaginal microbiome) and nine other species typically found in BV, by using the quantitative assay for bacterial viability described above. The engineered endolysin caused a 4–5 log<sub>10</sub>-fold loss of viability in three *Gardnerella* strains (Gs\_GS10234, Gs\_GS9838-1<sup>T</sup>, Gp\_UGent 18.01<sup>T</sup>), a 2–

18

349 3 log<sub>10</sub>-fold loss of viability in five strains (Gv\_ATCC 14018<sup>T</sup>, Gv\_BV50.1, Gl\_UGent 09.48,
350 Gp\_P80275, Gs\_BV7.1), and a 1–2 log<sub>10</sub>-fold loss of viability in a further five strains
351 (Gv\_UGent 09.07, Gv\_UGent 09.01, Gl\_BV13.2, Gl\_BV86.5, Gp\_UGent 21.28) (Figure 3A).
352 353 3A



Effect of PM-477 on Lactobacillus spp.



3C 357



Figure 3: PM-477 is highly specific for Gardnerella and spares lactobacilli and other BV 359 360 associated microbiome components. (a) Gardnerella strains, (b) Lactobacillus spp., (c) and Mobiluncus curtisii, Mobiluncus mulieris, Streptococcus agalactiae, Atopobium vaginae and 361 Prevotella bivia were tested for their susceptibility to PM-477 (20 µg/ml for 5h; treated, black 362 363 squares) and compared to buffer control-treated (untreated, white circles) bacteria suspensions. 364 For statistical purposes CFU/ml values from the untreated and the treated groups were lognormalized prior to applying the unpaired two-tailed multiple Student's *t*-test. *P*-values  $\leq 0.05$ 365 were considered statistically significant; \*\*  $P \leq 0.01$ , \*\*\*  $P \leq 0.001$ , \*\*\*\*  $P \leq 0.0001$ . 366

367

358

The same treatment of lactobacilli, by contrast, had no statistically significant effect on the 368 viability of any of the 12 strains tested (Figure 3B). It also had no effect on strains of Atopobium 369 vaginae, Mobiluncus mulieris, Prevotella bivia and Streptococcus agalactiae, and had only a 370 minor effect one of three strains tested of *Mobiluncus curtisii* (Figure 3C). (In the cases of 371 Atopobium vaginae and Prevotella bivia the cells either grew poorly or died rapidly upon 372

20

373	transfer from agar plates to suspension, even without treatment.) Thus, the engineered endolysin
374	PM-477 is highly selective for <i>Gardnerella</i> : it kills strains of each of the four main species <sup>23</sup> ,
375	without harming beneficial lactobacilli or other species typical of the vaginal microbiome.
376	The genus-specific bacteriolytic effect of PM-477 was confirmed by microscopy in mixed
377	cultures of Gardnerella and lactobacilli. These two genera can be distinguished by their distinct
378	morphologies: Gardnerella cells are small coccoidal rods, whereas lactobacilli form mostly
379	long and thick rods. PM-477 (at 460 µg/ml for 5 h) lysed G. vaginalis and G. swidsinskii cells
380	in mono-culture and selectively lysed them in mixed cultures of G. vaginalis and L. crispatus
381	and of G. swidsinskii and L. gasseri, respectively, while the lactobacilli in these mixed cultures
382	were unaffected (Figure 4A).

383

384 4A

Control G. vaginalis G.swidsinskii G.vaginalis + L.crispatus G.swidsinskii + L.gasseri

385

386 4B



22









Bacteriolytic effect of PM-477 on G.swidsinskii





390 4D

23

# Bactericidal effect of PM-477 on G.vaginalis







Bactericidal effect of PM-477 on G.swidsinskii





394 Figure 4: PM-477 selectively kills Gardnerella in a co-culture with lactobacilli. A, Phase contrast microscopy of dense cultures of G. vaginalis (ATCC14018T) (first row) and G. 395 swidsinskii (GS10234) (second row), or co-cultures of G. vaginalis (ATCC14018T) and L. 396 crispatus (LABCRI FB020-08c) (third row), as well as G. swidsinskii (GS10234) and L. gasseri 397 398 (LAB GAS LMG 9203T) (fourth row) treated with PM-477 (460 µg/ml for 5h) or with buffer (control). **B** and **C**, Cell counts of *Gardnerella* cells determined by phase contrast microscopy 399 after treatment with 25–400 µg/ml PM-477 for 5h or with buffer (Ctr). **D** and **E**, Viable cells 400

24

401 remaining ( $\log_{10}$  reduction CFU/ml compared to the buffer-treated control) in suspensions of 402 *Gardnerella* treated with 25–400 µg/ml PM-477 for 5h.

403

We compared the bactericidal and bacteriolytic effects of PM-477 on G. vaginalis and G. 404 *swidsinskii* by treating suspensions of the bacteria with 25–400 µg/ml PM-477 for 5 h and then 405 counting the cell numbers by microscopy and determining their viability by quantitative plating 406 (Figure 4B-E). The highest concentration of PM-477 (400 µg/ml) decreased the number of 407 408 cell-like structures by only 80–90 % (Figure 4B, C), whereas the same treatment resulted in a  $\geq$  5.6 log<sub>10</sub> reduction in viable cells. This indicates that PM-477 may kill before fully dissolving 409 bacterial cells, resulting in visible but dead cell-like structures seen under the microscope 410 (Figure 4D, E). 411

412

#### 413 Efficacy of PM 477 compared to standard antimicrobials

To compare the efficacy of PM-477 in suspension to the standard antimicrobials used to treat BV, we determined the minimum inhibitory concentration (MIC)s of PM-477, CLI, MDZ and TDZ for 20 strains of *Gardnerella* by following the Clinical and Laboratory Standards Institute protocol <sup>39</sup>. All the *Gardnerella* species tested were highly susceptible to PM-477 with a MIC<sub>90</sub> value (the MIC value which inhibits 90 % of strains) of 8  $\mu$ g/ml (**Table 1**).

419

420 **Table 1:** Minimum inhibitory concentration (MIC) of PM-477 and the antibiotics CLI, MDZ,

- 421 and TDZ for various *Gardnerella* spp. and *Lactobacillus* spp. (R) Resistance, defined as  $\geq$  32
- 422  $\mu$ g/ml for MDZ and TDZ, and  $\geq$  8  $\mu$ g/ml for CLI, according to international standards.

Gardnere	lla spp.		Μ	IC of Anti	microbials [µs	g/ml]
Name	Strain	Clade	PM-477	CLI	MDZ	TDZ
G. vaginalis (Gv9)	ATCC 14018T	IB	1	0.25	8	128 (R)
G. vaginalis (Gv1)	UGent 09.07	IA	2	0.25	>128 (R)	>128 (R)
G. vaginalis (Gv5)	UGent 09.01	IB	0.25	0.13	8	4
G. vaginalis (Gv8)	UGent 25.49	IB	0.13	< 0.06	8	4
G. vaginalis (BV50)	SJHBruges isolate		8	0.25	32	64 (R)
G. vaginalis (BV111)	SJHBruges isolate		2	0.125	8	4
G. vaginalis (FB049)	SJHBruges isolate		4	0.5	16	8
G. vaginalis (FB061)	SJHBruges isolate		8	0.25	8	4
G. leopoldii (Gl11)	UGent 09.48	II	4	0.5	128 (R)	128 (R)
G. leopoldii (BV13)	SJHBruges isolate		4	0.5	>128 (R)	>128 (R)
G. leopoldii (BV86)	SJHBruges isolate		1	0.25	>128 (R)	>128 (R)
G. piotii (Gp17)	UGent 18.01T	III	8	0.5	16	64 (R)
G. piotii (Gp22)	UGent 21.28	III	2	0.25	64 (R)	>128 (R)
G. piotii (P80275)	UGent isolate		1	0.5	16	32
G. piotii (FB041)	UGent isolate		4	1	32	64 (R)
G. piotii (VMF1800 SVT21)	SJHBruges isolate		8	1	32	64 (R)
G. swidsinskii (Gs23)	GS 10234	IV	0.5	0.25	64 (R)	>128 (R)
G. swidsinskii (Gs24)	GS 9838-1T	IV	0.25	< 0.06	>128 (R)	>128 (R)
G. swidsinskii (BV7)	SJHBruges isolate		1	0.5	>128 (R)	128 (R)
G. swidsinskii (BV112)	SJHBruges isolate		1	0.06	64 (R)	64 (R)
L. crispatus	DSM 20584		>128	4	>128	>128
L. gasseri	DSM 20077		>128	64	>128	>128
L. jensenii	PB2003-073-T2-3		>128	2	>128	>128

423

(R) Resistance, defined as  $\geq$  32 µg/ml for MDZ and TDZ and  $\geq$  8 µg/ml for CLI according to

international standards. 424

425

The G. swidsinskii strains had MICs in the range of  $0.25-1 \mu g/ml$ , whereas the G. vaginalis 426 strains had MICs of 0.13–8 µg/ml, and *G. leopoldii and G. piotii* strains had MICs of 1–8 µg/ml. 427 428 Among this small number of strains tested for each species, there was no evidence that the four Gardnerella species differed with regard to their susceptibility to PM-477. Whereas 12 of the 429 20 Gardnerella strains were resistant to MDZ and 15 were resistant TDZ, CLI was effective 430 against all strains at MICs  $\leq 1 \mu g/ml$ . All tested strains of three *Lactobacillus* species (L. 431 crispatus, L. gasseri, and L. jensenii) were resistant to the highest concentrations of PM-477, 432 MDZ, and TDZ (MICs > 128  $\mu$ g/ml), whereas only one strain was resistant to CLI. 433 Efficacy of PM-477 against biofilms of Gardnerella in human BV samples 434

26

To analyze the efficacy of PM-477 in a physiological environment that resembles closely the *in vivo* situation, we treated vaginal swabs from 15 BV patients, and analyzed them by fluorescence in-situ hybridization (FISH).

438



440

5B





27

Figure 5: PM-477 dissolves the Gardnerella-dominated biofilm on exfoliated vaginal 442 epithelial cells from BV patients. A, Representative examples of multi-color FISH with Gard 443 Cy3 probe (Gardnerella, yellow fluorescence) and universal Eub 338 Cy5 probe (all bacteria, 444 red fluorescence) in 400x magnification (where not stated otherwise) for patients 11, 12 and 15. 445 446 Baseline (prior to treatment): Gardnerella bacteria are cohesive and adherent to epithelial cells forming dense biofilm patches on the surface of clue cells which is apparent due to background 447 fluorescence. The attachment of *Gardnerella* biofilm to epithelial cells can be seen especially 448 well in DAPI stains and on zoomed original microphotographs (DAPI microphotographs are 449 added to supplementary material together with all other original microphotographs of Figure 5) 450 Control: Gardnerella dominated biofilms in buffer-treated controls after 24 h incubation are 451 452 still dense in patient 11 and 12 and start to partially disintegrate in patient 15. PM-477: After incubation with PM-477, the Gardnerella biofilm is completely disintegrated in all patients. 453 The disappearance of intense yellow fluorescent Gardnerella bacteria unmasks the red 454 fluorescence of still intact bacterial mass. Octenisept: similar to PM-477, Octenisept massively 455 reduces Gardnerella (yellow) but additionally nearly completely eliminates any other non-456 Gardnerella bacteria (red). B, Gardnerella cell density in samples of patients 1-15 expressed 457 as the number of yellow bacteria counted in areas containing 10 epithelial cells (see methods 458 459 for a detailed description of the counting method)., p-values were calculated with ANOVA in GraphPad Prism. 460

461

Areas of strong yellow fluorescence in the untreated (baseline) and buffer control-treated samples indicated the presence of *Gardnerella*-dominated biofilm on exfoliated vaginal epithelial cells (visible due to their pale autofluorescence and clearly corresponding to DAPI counterstain), called clue cells. At baseline and after buffer treatment, the yellow fluorescence of the *Gardnerella* probe outshines the red fluorescence of the probe for all bacteria, indicating

28

that the biofilm is composed in large part of Gardnerella cells. Figure 5A shows a total 467 468 resolution of the dense yellow staining on the epithelial cells upon treatment with PM-477. Therefore, PM 477 proved strong bacteriolytic activity also in this ex-vivo setting. The 469 specificity of PM-477 was demonstrated by the remaining red signal from the universal 470 bacterial probe, indicating mostly non-Gardnerella cells. Only very few individual Gardnerella 471 cells seemed to remain associated with or in between the epithelial cells. However, the 472 comparison of bacteriolytic and bactericidal effect in Figure 4B-E would indicate that these 473 might be dead cell-like structures with sufficient DNA associated to them to hybridize the FISH 474 probes. In contrast to PM-477, Octenisept killed and lysed both the Gardnerella and other 475 476 bacterial cells non-specifically, as indicated by the visible reduction of both types of 477 fluorescence.

The effect of treatment was also quantified by counting the number of bacterial cells per 10 478 epithelial cells in representative fields of vision (Figure 5B). When compared with the baseline 479 samples, no significant changes were observed upon incubation with the buffer control, 480 indicating that the vaginal microbiome was generally stable over the time-course of the 481 experiment. PM-477 significantly reduced Gardnerella cells in the patient samples (median of 482 483 300 cells/10 epithelial cells) when compared to baseline (median of 1200 cells/10 epithelial 484 cells, p=0.02) and when compared to the buffer control-treated samples (median of 900 cells/ 485 10 epithelial cells, p=0.007): 3 of the 15 samples showed a >500-fold reduction in *Gardnerella* 486 load, 4 showed a >100-fold reduction, 7 a >10-fold reduction and 11 a >2-fold reduction (data 487 for individual patient samples are presented in **Supplementary Table 3**).

488 The effects of PM-477 on *Gardnerella* were similar to those of Octenisept<sup>®</sup>. Unlike PM-477,

489 however, the lytic activity of the disinfectant was not specific for *Gardnerella* but affected all

490 bacteria (**Figure 5A**, **Supplementary Table 3**).

Two other potential BV associated bacteria, *A. vaginae* and *L. iners*, as well as *L. crispatus*,
were visualized by using selective FISH probes and their cell numbers per 10 epithelial cells

29

were counted (Supplementary Table 3). *A. vaginae*, *L. crispatus*, and *L. iners* were detected
in 10, 3 and 8 out of the 15 samples, respectively. Treatment with PM-477 reduced the median
cell counts of *L. iners* when compared to treatment with the buffer control in all samples
whereas the numbers of *L. crispatus* and *A. vaginae* bacteria were unaffected. Octenisept<sup>®</sup>
strongly reduced the cell counts of all three species.

In summary, these experiments provide a proof of the efficacy and selectivity of PM-477 for
the genus *Gardnerella in vitro* and also in the native BV biofilm.

500

#### 501 **Discussion**

This is the first study to show that prophage-derived endolysins active on *Gardnerella* could be used as an innovative treatment for bacterial vaginosis. Although no Gardnerella phages were ever isolated in a lab, we were able to identify putative endolysins *in silico*. We expressed them as recombinant proteins, improved their potency by systematic domain shuffling, demonstrated their efficacy and selectivity *in vitro*, and, ultimately, on the native polymicrobial biofilms in vaginal swabs from BV patients.

The currently available therapy of bacterial vaginosis is unsatisfactory. Antibiotic-centered 508 'standard-of-care' treatment for BV is associated with a recurrence rate of ~60 % within 6 509 510 months, which may be explained by low efficacy of antibiotics on bacteria growing as biofilms, but also by selective destruction of beneficial lactobacilli, which are thereby prevented from re-511 establishing a protective environment <sup>26</sup>. Bacteriophage-derived endolysins have been 512 described as a potential alternative to antibiotics; they are both highly active on mucosal 513 biofilms and selective for individual genera or even species of bacteria <sup>35</sup>. Neither endolysins 514 nor whole phages specific to *Gardnerella* have been isolated previously, although the existence 515 of Gardnerella-specific phages has been postulated on the basis of genomic analyses <sup>44</sup>. We 516 identified Gardnerella-specific endolysin genes in the prophage-like genome sequences of 517 518 strains of Gardnerella. A similar approach was reported earlier, in which the phage lysin PlyCD

30

was identified by searching prophage-like sequences in the genomes of *Clostridium difficile* strains <sup>48</sup>. The fact that it is possible to predict and generate endolysins from prophage encoded sequences in the genomes of unrelated species (*C. difficile* and *Gardnerella*) may indicate a wide application of this approach, which is easily adaptable to other pathogenic bacteria.

523 We could show that the wild-type endolysins we identified and, even more so, our engineered 524 constructs, are highly bactericidal and selective for the genus *Gardnerella*.

525 Our engineered endolysin PM-477 is superior to the current standard of care antibiotics in that 526 it is active in the low  $\mu$ g/ml range and effective against all 20 of the *Gardnerella* strains we 527 tested, covering all four named species. In total, 60 % of the 20 strains were resistant to MDZ 528 and 75 % to TZD, reinforcing the notion that PM-477 may be more effective against BV than 529 currently used standard antibiotics.

530 The high resistance rate for MDZ, which was also reported elsewhere <sup>31</sup>, does not support the 531 finding that MDZ treatment temporarily relieves the symptoms in a majority of cases <sup>26</sup>. 532 However, long-term cure is mostly not achieved with MDZ indicating that their effectiveness 533 may be reduced due to the high resistance rate of *Gardnerella* strains-<sup>49</sup>.

In our study, CLI was also effective against all the strains of different *Gardnerella* genotypes we tested. Curiously, however, CLI has not shown superior efficacy when compared to MDZ in clinical trials <sup>26</sup>, which may indicate that BV biofilms are more tolerant to CLI than they are of MDZ, thus compensating the higher rate of resistance against MDZ.

In conclusion, PM-477 is superior to all tested antibiotics because, unlike nitroimidazoles, it is active on all *Gardnerella* strains and, unlike CLI, it does not kill lactobacilli. Antibiotics may have the advantage over PM-477 of being active against a broader spectrum of pathogens. But, unlike *Gardnerella*, these pathogens may not be pivotal in vaginal biofilm formation as is the case in BV. Also, antibiotics typically have low activity on bacteria in biofilms <sup>27</sup> whereas our *ex-vivo* data indicate that PM-477 works well on *Gardnerella* in vaginal biofilms.

31

Progress has been made in developing animal models for BV. For example, it was possible to 544 model some of the clinical characteristics of BV, such as epithelial exfoliation and clue cells 545 upon infection of mice with *Gardnerella*<sup>50</sup>. However, it was not possible so far to model the 546 increase in pH and the diverse microbiome composition of human BV in animals. Therefore, 547 the next best and, arguably, more biologically relevant model to test the efficacy of PM-477 is 548 to use ex-vivo vaginal samples from BV patients, which contain clue cells, i.e. exfoliated 549 epithelial cells covered with a polymicrobial biofilm. The microbial populations of all the ex 550 vivo samples that we collected from 15 individual BV patients were clearly dominated by 551 Gardnerella and a substantial part of the Gardnerella cells adhered to the epithelial cells. 552 Treatment with PM-477 fully resolved the dense staining due to Gardnerella cells on the 553 554 epithelial cells while not affecting non-Gardnerella cells. Thus, we conclude that PM-477 quantitatively removes Gardnerella cells inside the polymicrobial biofilm on vaginal epithelial 555 556 cells ex vivo. Furthermore, it is effective in the environment of the vaginal fluid despite the putative presence of proteases <sup>51</sup> and other substances that might reduce its activity. 557

PM-477 shows promising results in vitro and ex vivo but we do not know yet whether selectively 558 removing Gardnerella will be sufficient to resolve the clinical symptoms of BV, which are 559 560 caused by a polymicrobial biofilm, and to allow lactobacilli to re-colonize the vagina. The increasing evidence of the central role that *Gardnerella* plays in the etiology of BV<sup>15</sup> and the 561 observation that BV seems not to be possible without *Gardnerella*<sup>22</sup>, indicates that this might 562 well be the case. The biomass of the polymicrobial biofilm consists largely of Gardnerella cells 563 <sup>52,53</sup>, so selective removal of *Gardnerella* should decimate the biofilm. Moreover, *Gardnerella* 564 mediates adhesion to the epithelial cells, whereas other bacteria, especially in smaller numbers, 565 may not be able to initiate biofilm formation on these cells <sup>54</sup>. Other pathogens, especially 566 567 Prevotella bivia, synergize with Gardnerella, so when the latter is removed the viability of the other pathogens is likely reduced as well <sup>55,56</sup>. Removal of *Gardnerella* (and the concomitant 568 reduction in the viability of *P. bivia*) would reduce the levels of sialidase produced by 569

32

*Gardnerella* and *P. bivia* and allow the mucus layer to reform, in turn reducing the adherence of the remaining BV pathogens and depriving them of carbon sources <sup>57</sup>. Finally, the active suppression of lactobacilli by *Gardnerella* <sup>22</sup> would be released, allowing recolonization by benign bacteria. This hypothesis has been investigated with *in vitro* biofilm models <sup>17,20</sup>, and PM-477 as a selective antimicrobial agent may be a very useful tool to further investigate the role of *Gardnerella* in *ex vivo* as well as in *in vivo* studies.

576 In summary, we report here that an engineered, phage-derived endolysin has the potential to

577 completely disrupt the *Gardnerella*-dominated biofilm in vaginal swabs from patients with BV.

578 PM-477 is, thus a promising candidate for an effective treatment of recurrent BV, which

remains, despite decades of research, a major public health concern.

580

## 581 Acknowledgements

We thank Grégory Resch and Life Science Editors for scientific editing assistance during thepreparation of the manuscript.

584

## 585 **References**

- 5861.Bautista CT, Wurapa E, Sateren WB, Morris S, Hollingsworth B, Sanchez JL. Bacterial
- 587 vaginosis: A synthesis of the literature on etiology, prevalence, risk factors, and
- relationship with chlamydia and gonorrhea infections. *Mil Med Res*. 2016;3(1):4.
- doi:10.1186/s40779-016-0074-5
- 590 2. Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis:
  a systematic review. *Am J Obstet Gynecol.* 2013;209(6):505-523.
- 592 doi:10.1016/j.ajog.2013.05.006
- 593 3. Tabatabaei N, Eren A, Barreiro L, et al. Vaginal microbiome in early pregnancy and
- 594 subsequent risk of spontaneous preterm birth: a case-control study. BJOG An Int J

33

595		Obstet Gynaecol. 2019;126(3):349-358. doi:10.1111/1471-0528.15299
596	4.	Leitich H, Kiss H. Asymptomatic bacterial vaginosis and intermediate flora as risk
597		factors for adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol.
598		2007;21(3):375-390. doi:10.1016/j.bpobgyn.2006.12.005
599	5.	Haahr T, Zacho J, Bräuner M, Shathmigha K, Skov Jensen J, Humaidan P.
600		Reproductive outcome of patients undergoing in vitro fertilisation treatment and
601		diagnosed with bacterial vaginosis or abnormal vaginal microbiota: a systematic

- 602 PRISMA review and meta-analysis. *BJOG An Int J Obstet Gynaecol*. 2019;126(2):200-
- 603 207. doi:10.1111/1471-0528.15178
- Mania-Pramanik J, Kerkar SC, Salvi VS. Bacterial vaginosis: A cause of infertility? *Int J STD AIDS*. 2009;20(11):778-781. doi:10.1258/ijsa.2009.009193
- 606 7. van Oostrum N, De Sutter P, Meys J, Verstraelen H. Risks associated with bacterial

607 vaginosis in infertility patients: a systematic review and meta-analysis. *Hum Reprod*.

608 2013;28(7):1809-1815. doi:10.1093/humrep/det096

- 8. Unemo M, Bradshaw CS, Hocking JS, et al. Sexually transmitted infections: challenges
  ahead. *Lancet Infect Dis.* 2017;17(8):e235-e279. doi:10.1016/S1473-3099(17)30310-9
- 611 9. Hoang T, Toler E, DeLong K, et al. The cervicovaginal mucus barrier to HIV-1 is

diminished in bacterial vaginosis. Silvestri G, ed. *PLOS Pathog*. 2020;16(1):e1008236.

613 doi:10.1371/journal.ppat.1008236

- 614 10. Vaneechoutte M. The human vaginal microbial community. *Res Microbiol*.
- 615 2017;168(9-10):811-825. doi:10.1016/j.resmic.2017.08.001
- 616 11. Ceccarani C, Foschi C, Parolin C, et al. Diversity of vaginal microbiome and
- 617 metabolome during genital infections. *Sci Rep.* 2019;9(1):1-12. doi:10.1038/s41598-
- 618 019-50410-x

619	12.	Petrova MI, Reid G, Vaneechoutte M, Lebeer S. Lactobacillus iners: Friend or Foe?
620		Trends Microbiol. 2017;25(3):182-191. doi:10.1016/j.tim.2016.11.007
621	13.	Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial
622		vaginosis. Obstet Gynecol. 2005;106(5):1013-1023.
623		doi:10.1097/01.AOG.0000183594.45524.d2
624	14.	Machado A, Cerca N. Influence of Biofilm Formation by Gardnerella vaginalis and
625		Other Anaerobes on Bacterial Vaginosis. J Infect Dis. 2015;212(12):1856-1861.
626		doi:10.1093/infdis/jiv338
627	15.	Muzny CA, Taylor CM, Swords WE, et al. An Updated Conceptual Model on the
628		Pathogenesis of Bacterial Vaginosis PubMed - NCBI. J Infect Dis.
629		2019;220(9):1399-1405. doi:10.1093/infdis/jiz342
630	16.	Swidsinski A, Loening-Baucke V, Mendling W, et al. Infection through structured
631		polymicrobial Gardnerella biofilms (StPM-GB). Histol Histopathol. 2014;29(5):567-
632		587. doi:10.14670/HH-29.10.567
633	17.	Castro J, Alves P, Sousa C, et al. Using an in-vitro biofilm model to assess the
634		virulence potential of bacterial vaginosis or non-bacterial vaginosis Gardnerella
635		vaginalis isolates. Sci Rep. 2015;5:11640. doi:10.1038/srep11640
636	18.	Castro J, Jefferson KK, Cerca N, Biomédicas E, Biomédicas B, Salazar A. Innate
637		immune components affect growth and virulence traits of bacterial-vaginosis-
638		associated and non-bacterial-vaginosis-associated Gardnerella vaginalis strains
639		similarly. Pathog Dis. 2019;76(9):89. doi:10.1093/femspd/fty089
640	19.	Murphy K, Mitchell CM. The Interplay of Host Immunity, Environment and the Risk
641		of Bacterial Vaginosis and Associated Reproductive Health Outcomes. J Infect Dis.
642		2016;214(Suppl 1):S29-S35. doi:10.1093/infdis/jiw140

643	20.	Castro J, Machado D, Cerca N. Unveiling the role of Gardnerella vaginalis in
644		polymicrobial Bacterial Vaginosis bio fi lms : the impact of other vaginal pathogens
645		living as neighbors. ISME J. 2019:1306-1317. doi:10.1038/s41396-018-0337-0
646	21.	Machado A, Jefferson KK a., Cerca N. Interactions between Lactobacillus crispatus
647		and bacterial vaginosis (BV)-associated bacterial species in initial attachment and
648		biofilm formation. Int J Mol Sci. 2013;14(6):12004-12012.
649		doi:10.3390/ijms140612004
650	22.	Schwebke JR, Muzny CA, Josey WE. Role of Gardnerella vaginalis in the pathogenesis
651		of bacterial vaginosis: A conceptual model. J Infect Dis. 2014;210(3):338-343.
652		doi:10.1093/infdis/jiu089
653	23.	Vaneechoutte M, Guschin A, Van Simaey L, Gansemans Y, Van Nieuwerburgh F,
654		Cools P. Emended description of Gardnerella vaginalis and description of Gardnerella
655		leopoldii sp. nov., Gardnerella piotii sp. nov. and Gardnerella swidsinskii sp. nov., with
656		delineation of 13 genomic species within the genus Gardnerella. Int J Syst Evol
657		Microbiol. 2019;69(3):679-687. doi:10.1099/ijsem.0.003200
658	24.	Hill JE, Albert AYK. Resolution and cooccurrence patterns of gardnerella leopoldii, G.
659		Swidsinskii, G. Piotii, and G. Vaginalis within the vaginal microbiome. Infect Immun.
660		2019;87(12). doi:10.1128/IAI.00532-19
661	25.	Shipitsyna E, Krysanova A, Khayrullina G, et al. Quantitation of all Four Gardnerella
662		vaginalis Clades Detects Abnormal Vaginal Microbiota Characteristic of Bacterial
663		Vaginosis More Accurately than Putative G. vaginalis Sialidase A Gene Count. Mol
664		Diagnosis Ther. 2019;23(1):139-147. doi:10.1007/s40291-019-00382-5

Bradshaw CS, Sobel JD. Current Treatment of Bacterial Vaginosis-Limitations and
Need for Innovation. *J Infect Dis* (8). 2016;214(S1):14-20. doi:10.1093/infdis/jiw159

- 667 27. Swidsinski A, Mendling W, Loening-Baucke V, et al. An adherent Gardnerella
- 668vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral
- 669 metronidazole. *Am J Obstet Gynecol*. 2008;198(1):97.e1-6.
- 670 doi:10.1016/j.ajog.2007.06.039
- 671 28. Sobel JD. Vulvovaginal candidosis. *Lancet*. 2007;369(9577):1961-1971.
- 672 doi:10.1016/S0140-6736(07)60917-9
- 673 29. Buffie CG, Jarchum I, Equinda M, et al. Profound alterations of intestinal microbiota
- 674 following a single dose of clindamycin results in sustained susceptibility to Clostridium
- 675 difficile-induced colitis. *Infect Immun.* 2012;80(1):62-73. doi:10.1128/IAI.05496-11
- 676 30. Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. Clostridium difficile
- 677 infection following systemic antibiotic administration in randomised controlled trials: a
- 678 systematic review and meta-analysis. *Int J Antimicrob Agents*. 2016;48(1):1-10.
- 679 doi:10.1016/j.ijantimicag.2016.03.008
- 680 31. Petrina MAB, Cosentino LA, Rabe LK, Hillier SL. Susceptibility of bacterial vaginosis
- 681 (BV)-associated bacteria to secnidazole compared to metronidazole, tinidazole and
- 682 clindamycin HHS Public Access. *Anaerobe*. 2017;47:115-119.
- 683 doi:10.1016/j.anaerobe.2017.05.005
- 684 32. Swidsinski A, Loening-Baucke V, Swidsinski S, Verstraelen H. Polymicrobial
- 685 Gardnerella biofilm resists repeated intravaginal antiseptic treatment in a subset of
- 686 women with bacterial vaginosis: a preliminary report. Arch Gynecol Obstet.
- 687 2015;291(3):605-609. doi:10.1007/s00404-014-3484-1
- 688 33. Lev-Sagie A, Goldman-Wohl D, Cohen Y, et al. Vaginal microbiome transplantation in
- women with intractable bacterial vaginosis. *Nat Med.* 2019;25(10):1500-1504.
- 690 doi:10.1038/s41591-019-0600-6

37

- 691 34. Schmelcher M, Donovan DM, Loessner MJ. Bacteriophage endolysins as novel
- 692 antimicrobials. *Future Microbiol*. 2012;7(10):1147-1171. doi:10.2217/fmb.12.97
- 693 35. Fischetti VA. Development of phage lysins as novel therapeutics: A historical

694 perspective. *Viruses*. 2018;10(6):310. doi:10.3390/v10060310

- 695 36. Fischetti VA. Bacteriophage endolysins: a novel anti-infective to control Gram-positive
- 696 pathogens. *Int J Med Microbiol*. 2010;300(6):357-362.
- 697 doi:10.1016/j.ijmm.2010.04.002
- 698 37. Schuch R, Lee HM, Schneider BC, et al. Combination therapy with lysin CF-301 and
- antibiotic is superior to antibiotic alone for treating methicillin-resistant staphylococcus
- aureus-induced murine bacteremia. *J Infect Dis*. 2014;209(9):1469-1478.
- 701 doi:10.1093/infdis/jit637
- 702 38. Oliveira H, Melo LDR, Santos SB, et al. Molecular Aspects and Comparative
- Genomics of Bacteriophage Endolysins. *J Virol*. 2013;87(8):4558-4570.
- 704 doi:10.1128/jvi.03277-12
- 705 39. Carpenter DE, Karen Anderson Diane Citron CM, JoAnn Dzink-Fox BL, et al.
- 706 *Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria.*; 2018.
- 707 www.clsi.org. Accessed June 9, 2020.
- 40. Amsel R, Totten PA, Spiegel CA, Chen KCS, Eschenbach D, Holmes KK. Nonspecific
  vaginitis. Diagnostic criteria and microbial and epidemiologic associations. *Am J Med*.
- 710 1983;74(1):14-22. doi:10.1016/0002-9343(83)91112-9
- 71141.Swidsinski A, Loening-Baucke V. Evaluation of Polymicrobial Involvement Using
- Fluorescence In Situ Hybridization (FISH) in Clinical Practice. 2017:531-543.
- 713 doi:10.1007/978-3-662-52959-1\_52
- 42. Swidsinski A, Guschin A, Tang Q, et al. Vulvovaginal candidiasis: histologic lesions

715		are primarily polymicrobial and invasive and do not contain biofilms. Am J Obstet
716		Gynecol. 2019;220(1):91.e1-91.e8. doi:10.1016/j.ajog.2018.10.023
717	43.	Amann RI, Binder BJ, Olson RJ, Chisholm SW, Devereux R, Stahl DA. Combination
718		of 16S rRNA-targeted oligonucleotide probes with flow cytometry for analyzing mixed
719		microbial populations. Appl Environ Microbiol. 1990;56(6).
720	44.	Malki K, Shapiro JW, Price TK, et al. Genomes of Gardnerella Strains Reveal an
721		Abundance of Prophages within the Bladder Microbiome. Kuo C-H, ed. PLoS One.
722		2016;11(11):e0166757. doi:10.1371/journal.pone.0166757
723	45.	Bohr LL, Mortimer TD, Pepperell CS. Lateral Gene Transfer Shapes Diversity of
724		Gardnerella spp. Front Cell Infect Microbiol. 2020;10. doi:10.3389/fcimb.2020.00293
725	46.	Schmelcher M, Tchang VS, Loessner MJ. Domain shuffling and module engineering of
726		Listeria phage endolysins for enhanced lytic activity and binding affinity. Microb
727		Biotechnol. 2011;4(5):651-662. doi:10.1111/j.1751-7915.2011.00263.x
728	47.	Nelson DC, Schmelcher M, Rodriguez-Rubio L, et al. Endolysins as Antimicrobials.
729		In: Advances in Virus Research. Vol 83. Academic Press Inc.; 2012:299-365.
730		doi:10.1016/B978-0-12-394438-2.00007-4
731	48.	Wang Q, Euler CW, Delaune A, Fischetti VA. Using a novel lysin to help control
732		Clostridium difficile infections. Antimicrob Agents Chemother. 2015;59(12):7447-
733		7457. doi:10.1128/AAC.01357-15
734	49.	Schuyler JA, Mordechai E, Adelson ME, Sobel JD, Gygax SE, Hilbert DW.
735		Identification of intrinsically metronidazole-resistant clades of Gardnerella vaginalis.
736		Diagn Microbiol Infect Dis. 2016;84(1):1-3. doi:10.1016/j.diagmicrobio.2015.10.006
737	50.	Morrill S, Gilbert NM, Lewis AL. Gardnerella vaginalis as a Cause of Bacterial
738		Vaginosis: Appraisal of the Evidence From in vivo Models. Front Cell Infect

|--|

- 51. Muytjens CMJ, Vasiliou SK, Oikonomopoulou K, Prassas I, Diamandis EP. Putative
- 741 functions of tissue kallikrein-related peptidases in vaginal fluid. *Nat Rev Urol*.
- 742 2016;13(10):596-607. doi:10.1038/nrurol.2016.161
- 74352.Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent Biofilms in Bacterial
- 744 Vaginosis. *Obs Gynecol*. 2005;106(5):1013-1022.
- 53. Swidsinski A, Doerffel Y, Loening-Baucke V, et al. Gardnerella biofilm involves
- females and males and is transmitted sexually. *Gynecol Obstet Invest*. 2010;70(4):256-
- 747 263. doi:10.1159/000314015
- 54. Alves P, Castro J, Sousa C, Cereija TB, Cerca N. Gardnerella vaginalis Outcompetes
- 29 other bacterial species isolated from patients with bacterial vaginosis, using in an in
  vitro biofilm formation model. *J Infect Dis*. 2014;210(4):593-596.
- 751 doi:10.1093/infdis/jiu131
- 752 55. Pybus V, Onderdonk AB. Evidence for a commensal, symbiotic relationship between
- 753 Gardnerella vaginalis and Prevotella bivia involving ammonia: Potential significance
- 754 for bacterial vaginosis. *J Infect Dis*. 1997;175(2):406-413.
- 755 doi:10.1093/infdis/175.2.406
- 56. Chen KCS, Forsyth PS, Buchanan TM, Holmes KK. Amine content of vaginal fluid
  from untreated and treated patients with nonspecific vaginitis. *J Clin Invest*.
- 758 1979;63(5):828-835. doi:10.1172/JCI109382
- 57. Briselden AM, Moncla BJ, Stevens CE, Hillier SL. Sialidases (neuraminidases) in
  bacterial vaginosis and bacterial vaginosis-associated microflora. *J Clin Microbiol*.
  1992;30(3).